27685-94-5

Usage

Uses

Used in Chemical Industry:
4-Chlorothieno[3,2-c]pyridine is used as an intermediate compound for the synthesis of various complex organic molecules. Its unique structure allows it to serve as a building block in the creation of new chemical entities, which can be further modified or functionalized to achieve desired properties.
Used in Pharmaceutical Industry:
4-Chlorothieno[3,2-c]pyridine is used as a potential starting material for the development of new drugs. Given its phenylpiperidine backbone, it shares structural similarities with known pharmaceutical compounds, such as fentanyl, a potent synthetic opioid analgesic. This suggests that 4-Chlorothieno[3,2-c]pyridine could be a promising candidate for the design and synthesis of novel therapeutic agents, particularly in the area of pain management or other medical applications where phenylpiperidine-based drugs are effective.
While the specific uses or properties of 4-Chlorothieno[3,2-c]pyridine are not extensively documented in the general literature, its potential applications in the chemical and pharmaceutical industries are promising, given its structural characteristics and the versatility of the phenylpiperidine class of compounds. Further research and development could unlock its full potential and contribute to the advancement of new chemical and pharmaceutical products.

InChI:InChI=1/C7H4ClNS/c8-7-5-2-4-10-6(5)1-3-9-7/h1-4H

Upstream product

• 27685-92-3 4-oxo-4,5-dihydrothieno[3,2-c]pyridine 
• 88-13-1 3-Thiophene carboxylic acid 

Downstream Products

• 29079-76-3 (3,4-dimethoxy-phenyl)-thieno[3,2-c]pyridin-4-yl-acetonitrile 
• 85517-58-4 4-(4-Methoxybenzyl)-thieno<3,2-c>pyridin 
• 106261-27-2 4-(1-piperazinyl)thieno<3,2-c>pyridine 
• 27685-95-6 4-hydrazinylthieno[3,2-c]pyridine 
• 1609577-15-2 4-[4-(1-methyl-1H-pyrazol-5-yl)phenoxy]thieno[3,2-c]pyridine 
• 1609356-15-1 4-methyl-3-(thieno[3,2-c]pyridin-4-yl)aniline 
• 1609356-14-0 4-(2-methyl-5-nitrophenyl)thieno[3,2-c]pyridine 
• 1609356-13-9 C₁₃H₁₀N₂S 
• 1609356-12-8 C₁₃H₈N₂O₂S 
• 1609356-16-2 4-chloro-3-(thieno[3,2-c]pyridin-4-yl)aniline 
• 1609356-11-7 4-(2-chloro-5-nitrophenyl)thieno[3,2-c]pyridine 
• 85517-66-4 4-(3,4-Dimethoxybenzyl)-5-methyl-4,5-dihydrothieno<3,2-c>pyridin 
• 85517-61-9 4-(3,4-Dimethoxybenzyl)-5-methylthieno<3,2-c>pyridinium-iodid 

Relevant academic research and scientific papers

Organic metal compound and organic light-emitting device

Organic metal compounds and organic light-emitting devices employing the same are provided. The organic metal compound has a chemical structure of Formula (I) or Formula (II): In particular, one of the following two conditions (1) and (2) is met: (1) R1 is deuterium or C1-6 deuterated alkyl group, when R3 and R4 are independently hydrogen, halogen, C1-6 alkyl group, C1-6 fluoroalkyl or C3-12 heteroaryl group; and (2) R1 is hydrogen, deuterium, C1-6 alkyl group, C1-6 deuterated alkyl group, C3-12 heteroaryl group, or C6-12 aryl group, when at least one of R3 and R4 is C6-12 aryl group or C6-12 fluoroaryl group.

EZH2 Inhibitors

The present invention relates to compounds that inhibit EZH2 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Design and synthesis of piperazinylpyridine derivatives as novel 5-HT 1A agonists/5-HT3 antagonists for the treatment of irritable bowel syndrome (IBS)

We have prepared a series of piperazinylpyridine derivatives for the treatment of irritable bowel syndrome (IBS). These compounds, which were designed by pharmacophore analysis, bind to both serotonin subtype 1A (5-HT 1A) and subtype 3 (5-HT3) receptors. The nitrogen atom of the isoquinoline, a methoxy group and piper-azine were essential to the pharmacophore for binding to these receptors. We also synthesized furo- and thienopyridine derivatives according to structure-activity relationship analyses. Compound 17c (TZB-20810) had high affinities to these receptors and exhibited 5-HT1A agonistic activity and 5-HT3 antagonistic activity concurrently, and is a promising drug for further development in the treatment of IBS.

Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

SUBSTITUTED SULFONIC ACID N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

The Thienopyridine and Furopyridine Rings: New Pharmacophores with Potential Antipsychotic Activity

Two new arylpiperazine derivatives, the 4-(1-piperazinyl)thieno- and -furopyridine ring systems, have been synthesized and appended via tetramethylene chains to various imide rings.Target compounds from each series were found to have significant activity in the blockade of apomorphine stereotypy and apomorphine-induced climbing, the Sidman avoidance response, and the conditioned avoidance response.In addition, while potent affinity for serotonin 5-HT1 and 5-HT2 receptors was observed for both the thieno- and furopyridine derivatives,the interaction of these molecules with the dopamine D2 receptor was weak.Electrophysiological studies of the lead prototypes from each series, involving compounds 22 and 33, indicate these two molecules have distinctively different effects on dopamine neurons in areas A9 and A10.Despite the similarity these molecules share in their behavioral indices of antipsychotic acivity, it is likely that the thieno- and furopyridine rings employ different mechanisms to achieve this convergence of biological effects.

Antipsychotic fused-ring pyridinylpiperazine derivatives

Disubstituted 1,4-piperazinyl derivatives are disclosed wherein one substituent is a bicyclic fused-ring furo-, pyrrolo-, cyclopentadieno-, or thieno-pyridine heterocyclic system and the second substituent is an alkylene chain attached to cyclic imide heterocycles, such as azaspiro[4.5]decanediones, dialkylglutarimides, thiazolidinediones, succinimides, and morpholine-2,6-diones; or a benzylic carbinol moiety. These compounds have potent antipsychotic and serotonin antagonist activities. 4-[4-[4-(4-Furo[3,2-c]pyridinyl)-1-piperazinyl]butyl]-3,5-morpholinedione is an example of a typical embodiment having selective antipsychotic activity.